ArticleNature2025
Evolutionary fingerprints of epithelial-to-mesenchymal transition.
Abstract read
In one paragraph
Article in Nature, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.
0numbers the graph read from it
0cells of the map it votes in
29citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed.
- Decoding epithelial-mesenchymal transitions with multi-omics.Nature reviews. Genetics · 2026Review
- The H63D Polymorphism in the HFE Gene Promotes Aggressive Disease Phenotypes in Pancreatic Ductal Adenocarcinoma.Clinical cancer research : an official journal of the American Association for Cancer Research · 2026Article
- ARNTL2 promotes metastatic phenotypes through SERPINE1 transcription in KRAS G12D pancreatic cancer.iScience · 2026Article
- Development of an immunocompetent cutaneous squamous cell carcinoma model identifies VISTA and CTLA-4 as targetable immune checkpoints.Journal for immunotherapy of cancer · 2026Article
- Hypoxia-induced metastatic heterogeneity in pancreatic cancer.Nature communications · 2026Article
- The basal cell state maintains pancreatic cancers by controlling an immunosuppressive circuit.bioRxiv : the preprint server for biology · 2026Article
- Cancer Heterogeneity and Cancer Cell Plasticity: Molecular Mechanisms and Precision Therapy.MedComm · 2026Review
- The Protein Phosphatase Inhibitor LB100 Targets the Mesenchymal Lineage of Pancreatic Ductal Adenocarcinoma.MedComm · 2026Article
- Hallmarks of epithelial-mesenchymal plasticity in cancer.Molecular cancer · 2026Review
- Epithelial-to-mesenchymal transition as a central driver of tumor cell plasticity.Nature cancer · 2026Review
- Extracellular Vesicles fromNanomaterials (Basel, Switzerland) · 2026Article
- [Anemoside B4 inhibits non-small cell lung cancer metastasis by modulating epithelial-mesenchymal transition mediated by the MAPK and Keap1/Nrf2 signaling pathways].Zhejiang da xue xue bao. Yi xue ban = Journal of Zhejiang University. Medical sciences · 2026Article
- Adipogenic transdifferentiation reprograms EMT-high PDAC cells into a post-mitotic adipocyte-like state and limits metastasis.Cell death & disease · 2026Article
- Early cellular plasticity promotes progression and dissemination in pancreatic adenocarcinoma.Cancer metastasis reviews · 2026Review
- Phosphorylation-dependent modulation of the Lamin A/C-EZH2 complex regulates epithelial-mesenchymal plasticity.Nucleic acids research · 2026Article
- Evolution of Cancer Metastases via Lineage Trans-Differentiation.Research (Washington, D.C.) · 2026Article
- Article
- Comprehensive tumor-immune profiling reveals mediators of paradoxical immune sensitivity in sarcomatoid renal cell carcinoma.Cancer cell · 2025Article
- EMT and cancer: what clinicians should know.Nature reviews. Clinical oncology · 2025Review
- Hypoxia-induced metastatic heterogeneity in pancreatic cancer.Research square · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
36 authors.
Luigi Perelli *Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. LPerelli@mdanderson.org.ORCID 0000-0001-7320-8193
Li Zhang *Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID 0000-0002-7750-6427
Sarah MangiameliBroad Institute of Harvard and MIT, Cambridge, MA, USA.
Francesca GianneseCenter for Omics Sciences, IRCCS San Raffaele Institute, Milan, Italy.ORCID 0000-0001-8695-649X
Krishnan K MahadevanDepartment of Cancer Biology, Metastasis Research Center, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Fuduan PengDepartment of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Francesca CitronDepartment of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID 0000-0002-5896-3008
Hania KhanDepartment of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Courtney LeDepartment of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID 0000-0003-4456-1478
Enrico GurreriDepartment of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID 0000-0002-7752-4641
Federica CarboneNerviano Medical Sciences, NMS Group, Milan, Italy.
Andrew J C RussellBroad Institute of Harvard and MIT, Cambridge, MA, USA.ORCID 0000-0001-5411-2807
Melinda SoeungDepartment of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID 0000-0002-6902-898X
Truong Nguyen Anh LamDepartment of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Sebastian LundgrenDepartment of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID 0000-0001-5135-558X
Sujay MarisettyDepartment of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Cihui ZhuDepartment of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Desiree CataniaTRACTION Platform, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Alaa M T MohamedDepartment of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Ningping FengTRACTION Platform, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Jithesh Jose AugustineDepartment of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Alessandro SgambatoDepartment of Translational Medicine and Surgery, Università Cattolica del Sacro Cuore, Rome, Italy.
Giampaolo TortoraDepartment of Translational Medicine and Surgery, Università Cattolica del Sacro Cuore, Rome, Italy.
Giulio F DraettaDepartment of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID 0000-0001-5225-9610
Giovanni TononCenter for Omics Sciences, IRCCS San Raffaele Institute, Milan, Italy.ORCID 0000-0003-2973-5038
Andrew FutrealDepartment of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID 0000-0001-8663-2671
Virginia GiulianiTRACTION Platform, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID 0000-0002-2439-4986
Alessandro CarugoDepartment of Biology, IRBM, Rome, Italy.ORCID 0000-0001-5182-3320
Andrea VialeDepartment of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Michael P KimDepartment of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Timothy P HeffernanTRACTION Platform, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID 0000-0002-3166-8922
Linghua WangDepartment of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID 0000-0001-9380-0266
Raghu KalluriDepartment of Cancer Biology, Metastasis Research Center, University of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID 0000-0002-2190-547X
Davide CittaroCenter for Omics Sciences, IRCCS San Raffaele Institute, Milan, Italy. cittaro.davide@hsr.it.ORCID 0000-0003-0384-3700
Fei ChenBroad Institute of Harvard and MIT, Cambridge, MA, USA. chenf@broadinstitute.org.ORCID 0000-0003-2308-3649
Giannicola GenoveseDepartment of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. GGenovese@mdanderson.org.ORCID 0000-0003-1392-9954
Funding
Tumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI DIANE BODURKA · 1985 to 2026
$290.8MCOVID19 Slide-seqR01HG010647 · NHGRI · BROAD INSTITUTE, INC. · PI Fei Chen, Evan Z Macosko · 2019 to 2026
$6.0MTumor cell lineage diversity and composition in gastric cancer progression and therapy resistanceR01CA266280 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Pawel K. Mazur, Linghua Wang · 2022 to 2026
$3.2MMitochondrial heterogeneity as the origin of chemoresistance in pancreatic cancerR01CA258917 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI VIALE, ANDREA · 2021 to 2025
$2.3MA Platform for Scalable Spatial Somatic Variant ProfilingUG3NS132135 · NINDS · BROAD INSTITUTE, INC. · PI BUENROSTRO, JASON DANIEL, CHEN, FEI · 2023 to 2024
$751kBurroughs Wellcome FundNCI NIH HHS P30 CA016672NCI NIH HHS R01 CA258917NCI NIH HHS R01 CA266280NHGRI NIH HHS R01 HG010647NINDS NIH HHS UG3 NS132135
Abstract
Mesenchymal plasticity has been extensively described in advanced epithelial cancers; however, its functional role in malignant progression is controversial
Indexed as
Clonal EvolutionEpithelial-Mesenchymal TransitionPancreatic NeoplasmsAnimalsCell LineageCell Line, TumorCell PlasticityCentromereChromatinChromothripsisDisease ProgressionFemaleGenomic InstabilityHumansMaleMiceChromatin
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.